Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS.
J Pept Sci · 2025
Last updated 2026-05-28A study tested how heat and light affect the stability of liraglutide, a GLP-1 drug used for type 2 diabetes and obesity. Using advanced lab methods, researchers found 10 impurities, including 4 new ones, that form when the drug breaks down under these conditions. The study also identified where these changes happen in the drug's structure.
AI summary of the abstract below.
| Journal | J Pept Sci, 2025 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
Abstract
Liraglutide (LGT), a synthetic glucagon-like peptide-1 (GLP-1) analogue, is widely used in the treatment of Type 2 diabetes and obesity. Due to its peptide-based nature, it is prone to degradation, particularly under improper storage or handling conditions. Environmental stressors, such as heat and light, can lead to the formation of impurities that may compromise the quality and safety of the drug. In this study, we have investigated the impact of thermal and photolytic stress on LGT stability using reverse-phase liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS). This method enabled the separation, identification, and characterization of intact LGT and its degradation products (DPs). Ten impurities were identified, including four DPs that have not been reported so far. Further, MS/MS fragmentation analysis was employed to elucidate the sequences of LGT and its impurities, pinpointing the modifications and their respective sites. The formation mechanisms of these impurities were also proposed, providing critical insights into the degradation pathways. This study offers a comprehensive analytical approach for assessing the stability of peptide drugs, contributing to enhanced quality control and safer pharmaceutical formulations.
Verbatim abstract via PubMed 40814845 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.